German pharmaceutical company BioNTech on Thursday started the construction of the first production site in Africa for vaccines based on messenger ribonucleic acid (mRNA). The plant in the Rwandan capital of Kigali will receive its first containers for production, so-called “BioNTainers,” in late 2022, a spokesperson for the company said. Production of vaccines will begin around 12 to 18 months after they have been installed. “The goal we pursue together with governments and regulatory authorities is to produce vaccines for Africa here with highly skilled professionals from Africa,” said BioNT…